Kinase Inhibitors Discovered to Trigger Widespread Protein Degradation Beyond Traditional Inhibition
核心洞察
A systematic study of 98 kinases and 1,570 inhibitors revealed that 232 compounds accelerate the degradation of their target proteins, affecting 66 different kinases.
Researchers identified three distinct mechanisms by which kinase inhibitors (搜索) push proteins into unstable states that trigger cellular quality-control machinery for removal.
The findings expand the therapeutic potential of existing kinase inhibitors (搜索) by demonstrating they can eliminate disease-driving proteins rather than just blocking their activity.
A groundbreaking international study has revealed that kinase inhibitors (搜索)—cornerstone drugs in cancer (搜索) therapy and other diseases—possess a previously underappreciated dual mechanism of action. Beyond their traditional role of blocking enzymatic activity, these medications also accelerate the destruction of their target proteins within cells, opening new avenues for therapeutic development.
The research, published in Nature and conducted by scientists at CeMM (搜索) (Research Center for Molecular Medicine of the Austrian Academy of Sciences), AITHYRA Institute (搜索) for Artificial Intelligence in Biomedicine in Vienna, and IRB Barcelona (搜索), systematically mapped this phenomenon across a comprehensive library of compounds.
Systematic Discovery Reveals Widespread Effect
The research team profiled 98 kinases against a library of 1,570 inhibitors, monitoring protein abundance over time to capture degradation events. The results demonstrated that 232 compounds lowered the levels of at least one kinase, with 66 different kinases affected across the panel.
"Inhibitor-induced degradation turns out to be surprisingly widespread," says Dr. Natalie Scholes, senior postdoctoral researcher at CeMM (搜索) and first author of the study. "Our data show that small molecules don't just block kinase activity; they can shift proteins into conformations that the cell recognizes as unstable. That means inhibitors can double as degraders, adding a whole new layer to how these drugs work."
The IRB Barcelona (搜索) team, led by Dr. Patrick Aloy, played a crucial role in developing the analytical framework that enabled systematic identification of degradation events across the inhibitor library. Dr. Aloy, along with Dr. Martino Bertoni and Dr. Arnau Comajuncosa-Creus, developed the drug-screen scoring strategy and supervised the associated data analysis.
Three Mechanisms, One Unifying Principle
While some degradation events followed the known "chaperone deprivation" pathway—where inhibitor binding prevents the stabilizing chaperone HSP90 (搜索) from protecting client kinases—many others revealed novel mechanisms. The researchers identified a shared principle: inhibitors can push kinases into altered states through changes in activity, localization, or assembly, creating naturally unstable conformations that cellular proteolytic circuits rapidly clear.
The team illustrated this principle through three distinct case studies. The kinase LYN (搜索) was eliminated within minutes once an inhibitor disrupted its natural stability switch. BLK (搜索) was degraded only after being released from the cell membrane into the cytosol by a membrane-bound protease complex. RIPK2 (搜索) was cleared after forming large protein clusters that the cell recognized and removed through its recycling machinery.
Implications for Drug Development
The findings challenge the traditional view of kinase inhibitors (搜索) as purely activity-blocking agents. With more than 80 kinase inhibitors currently FDA-approved and nearly twice as many in clinical development, this discovery could significantly impact how researchers approach drug design and understand existing therapies.
"These results redefine how we think about kinase inhibitors (搜索)," says Dr. Patrick Aloy, ICREA Research Professor and head of Structural Bioinformatics and Network Biology at IRB Barcelona (搜索). "Recognising protein degradation as part of their mechanism expands the possibilities for designing therapies that eliminate disease-driving proteins more effectively."
Dr. Georg Winter, Director at the AITHYRA Institute (搜索) for Biomedical AI and senior author of the study, emphasizes the broader implications: "This study demonstrates that degradation is not an anomaly but part of the pharmacological spectrum of kinase inhibitors (搜索). Understanding this dimension could help us design better drugs that don't just silence kinases but remove them altogether—and in some cases, it may explain unexpected effects of existing therapies."
The research positions kinase inhibitors (搜索) as natural tools for the emerging field of Targeted Protein Degradation (TPD), potentially expanding therapeutic options for diseases driven by faulty kinase activity, particularly cancer (搜索). This dual mechanism could lead to more effective treatments that completely eliminate problematic proteins rather than merely blocking their function.